Prognostic effect of selected additional genetic abnormalities among patients with ALL and CRLF2 deregulation
| . | EFS % (95% CI) at 5 y . | RFS % (95% CI) at 5 y . | OS % (95% CI) at 5 y . |
|---|---|---|---|
| IKZF1 deletion | 53 (29-72) | 67 (38-85) | 57 (32-76) |
| Normal | 63 (44-78) | 73 (52-86) | 80 (61-91) |
| HR (95% CI)* | 1.84 (0.79-4.26) | 1.92 (0.67-5.54) | 2.36 (0.97-5.72) |
| P | .157 | .227 | .058 |
| PAX5 deletion | 61 (35-79) | 69 (41-86) | 72 (46-87) |
| Normal | 60 (38-76) | 71 (46-86) | 72 (50-85) |
| HR (95% CI)* | 0.80 (0.31-2.03) | 0.87 (0.28-2.67) | 0.76 (0.28-2.07) |
| P | 0.635 | 0.803 | 0.593 |
| JAK2 mutation | 40 (12-67) | 86 (33-98) | 40 (12-67) |
| Normal | 80 (41-95) | 89 (43-98) | 90 (47-99) |
| HR (95% CI)* | 4.06 (0.81-20.38) | 1.70 (0.10-27.94) | 4.06 (0.81-20.38) |
| P | .088 | .710 | .088 |
| CDKN2A deletion | 75 (46-90) | 80 (50-93) | 81 (53-94) |
| Normal | 51 (31-68) | 63 (39-79) | 66 (45-81) |
| HR (95% CI)* | 0.52 (0.19-1.44) | 0.61 (0.19-1.99) | 0.46 (0.15-1.40) |
| P | .206 | .413 | .170 |
| . | EFS % (95% CI) at 5 y . | RFS % (95% CI) at 5 y . | OS % (95% CI) at 5 y . |
|---|---|---|---|
| IKZF1 deletion | 53 (29-72) | 67 (38-85) | 57 (32-76) |
| Normal | 63 (44-78) | 73 (52-86) | 80 (61-91) |
| HR (95% CI)* | 1.84 (0.79-4.26) | 1.92 (0.67-5.54) | 2.36 (0.97-5.72) |
| P | .157 | .227 | .058 |
| PAX5 deletion | 61 (35-79) | 69 (41-86) | 72 (46-87) |
| Normal | 60 (38-76) | 71 (46-86) | 72 (50-85) |
| HR (95% CI)* | 0.80 (0.31-2.03) | 0.87 (0.28-2.67) | 0.76 (0.28-2.07) |
| P | 0.635 | 0.803 | 0.593 |
| JAK2 mutation | 40 (12-67) | 86 (33-98) | 40 (12-67) |
| Normal | 80 (41-95) | 89 (43-98) | 90 (47-99) |
| HR (95% CI)* | 4.06 (0.81-20.38) | 1.70 (0.10-27.94) | 4.06 (0.81-20.38) |
| P | .088 | .710 | .088 |
| CDKN2A deletion | 75 (46-90) | 80 (50-93) | 81 (53-94) |
| Normal | 51 (31-68) | 63 (39-79) | 66 (45-81) |
| HR (95% CI)* | 0.52 (0.19-1.44) | 0.61 (0.19-1.99) | 0.46 (0.15-1.40) |
| P | .206 | .413 | .170 |
ALL indicates acute lymphoblastic leukemia; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; and RFS, relapse-free survival.
Hazard ratio from univariate Cox model.